Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jad Chahoud"'
Autor:
Ali Hajiran, Logan Zemp, Da David Jiang, Elizabeth Green, Nicholas H. Chakiryan, Wade J. Sexton, Lee A. Hugar, Scott M. Gilbert, Michael A. Poch, Jad Chahoud, Brandon J. Manley, Kyle A. Gillis, Jingsong Zhang, Rohit Jain, Roger Li
Publikováno v:
Journal of Urology. 206:924-932
Patients with muscle invasive bladder cancer (MIBC) of variant histology have a poor prognosis. It is unclear if neoadjuvant chemotherapy prior to radical cystectomy is associated with pathological downstaging or improved overall survival (OS) for pa
Autor:
Jingsong Zhang, Logan Zemp, Scott M. Gilbert, Ali Hajiran, Wade J. Sexton, Rohit Jain, Roger Li, Nicholas H. Chakiryan, Lee A. Hugar, Brandon J. Manley, Jad Chahoud, Da David Jiang, Elizabeth Green, Kyle A. Gillis
Publikováno v:
Urologic oncology. 40(3)
Clinical trials have not shown a significant overall survival (OS) difference between chemotherapy and immunotherapy as first-line agents in metastatic urothelial carcinoma (UC). However, the generalizability of these findings in a real-world setting
Autor:
Philippe E. Spiess, Carlos Moran-Segura, Ali Hajiran, John M. Koomen, Jose Laborde, Jonathan Nguyen, Nick Chakiryan, Wade J. Sexton, Young-Chul Kim, Jad Chahoud, Logan Zemp, Brandon J. Manley, Saif Zaman, Esther Katende, Michelle Fournier, Shayan Falasiri, Jamie K. Teer, Jasreman Dhillon, Ahmet M. Aydin, Susan McCarthy, James J. Mulé
Publikováno v:
Clin Exp Immunol
Summary A clearer understanding of the tumor immune microenvironment (TIME) in metastatic clear cell renal cell carcinoma (ccRCC) may help to inform precision treatment strategies. We sought to identify clinically meaningful TIME signatures in ccRCC.
Autor:
Amishi Yogesh Shah, Matthew T. Campbell, Kanishka Sircar, Padmanee Sharma, Surena F. Matin, Sangeeta Goswami, Pavlos Msaouel, Eric Jonasch, Lianchun Xiao, Barrett McCormick, Nizar M. Tannir, Jianjun Gao, Jeremy A. Ross, Jose A. Karam, Amado J. Zurita, Tharakeswara K. Bathala, Jad Chahoud, Robert Horn, Christopher G. Wood
Publikováno v:
Urologic oncology. 39(2)
Introduction Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-
Autor:
Julio M. Pow-Sang, Ahmet M. Aydin, Ali Hajiran, Logan Zemp, Salim Cheryian, Jad Chahoud, Phillippe E. Spiess
Publikováno v:
Urologic oncology. 39(1)
Purpose The toxicity of topical chemotherapeutics has been well-characterized in extra-genital squamous cell carcinoma; however, there is limited data regarding the use of topical agents for penile squamous cell carcinoma in situ (CIS). We aim to des
Autor:
Guru Sonpavde, Andrew Lai, Mounsif Azizi, Lance C. Pagliaro, Andrea Necchi, Ahmet M. Aydin, Charles C. Peyton, Jad Chahoud, Philippe E. Spiess, Ali Hajiran, Ambuj Kumar, Suks Minhas
Publikováno v:
The Journal of urology. 203(6)
PURPOSE: Neoadjuvant chemotherapy is a recommended treatment for patients with penile cancer with bulky inguinal lymphadenopathy or unresectable primary tumors, although there is no evidence of its benefit from randomized trials. MATERIALS AND METHOD
Autor:
Jad, Chahoud, Dawen, Sui, William D, Erwin, Alison M, Gulbis, Martin, Korbling, Mingzhi, Zhang, Sairah, Ahmed, Gheath, Alatrash, Paolo, Anderlini, Stefan O, Ciurea, Betul, Oran, Luis E, Fayad, Roland L, Bassett, Elias J, Jabbour, L Jeffrey, Medeiros, Homer A, Macapinlac, Ken H, Young, Issa F, Khouri
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10)
PURPOSE: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan ((90)YIT) in patients with relapsed diffuse large B